Compare CGBD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | PHAT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | CGBD | PHAT |
|---|---|---|
| Price | $10.90 | $11.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $12.92 | ★ $19.83 |
| AVG Volume (30 Days) | 567.1K | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $3.74 | $93.04 |
| Revenue Next Year | $1.80 | $58.91 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $10.62 | $3.92 |
| 52 Week High | $14.32 | $18.31 |
| Indicator | CGBD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 45.14 |
| Support Level | $10.68 | $11.04 |
| Resistance Level | $12.17 | $13.16 |
| Average True Range (ATR) | 0.29 | 0.69 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 13.29 | 13.84 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.